Medaisp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Medai is involved in the development of innovative diagnostic methods, including the OVARIANA® application that supports ovarian cancer diagnostics and therapy recommendations. The company also specializes in 3D reconstruction of bone structures affected by tumors for orthopedic surgery and utilizes artificial intelligence for early detection of prostate cancer. Additionally, Medai has coordinated the accelerated production of COVID-19 tests during the pandemic.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-09-24. Active
06 2530 0008 2048 1065 6806 0001
Debt
1 closed proceeding recorded in KRZ history. Closed proceedings in history
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| May 7, 2025 | Discontinued enforcement proceedings | Closed |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,904 | Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk | |
| Jun 25, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282 | PREZYDENT MIASTA BIELSKO-BIAŁA |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Daria Magdalena Przegalińska Szewczulak (47) | 97 | $1,310.10 | 97% |
Others | 3 | $40.52 | 3% |
Beneficial owners
| Person | Rights |
|---|---|
Daria Magdalena Przegalińska-Szewczulak (47)  | Shareholder of a limited liability company, 4850.0 PLN |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| New Valuesp. z o.o. | $64,335.86 | new-value.pl | |
| Biostat Research And Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | |
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | |
| Emo-Linksp. z o.o. | $43,353.20 | emo-link.com | |
| Advanced Diagnostic Equipmentsp. z o.o. | $43,171.56 | adediabetics.pl | |
| Edoktor24 Servicessp. z o.o. | $34,089.64 | edoktor24.pl | |
| CannamedaiS.A. | $28,203.90 | cannamedai.com | |
| NanovelosS.A. | $24,842.03 | nanovelos.com | |
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | |
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com |
Change history
| Date | Event |
|---|---|
| 2022-06-09 | PKD change (Removed: 62, 63.11.Z, 68, 71.12, 71.20.B; Added: 18, 46, 47.91.Z, 47.99.Z, 59.1, 70.10.Z, 73, 74, 85.59) |
| 2020-10-14 | Address change (Ul. Grawerska 21, 43-300, Bielsko-Biała → Ul. Prof. Dr. Mieczysława Michałowicza 12, 43-300, Bielsko-Biała) |
| 2020-02-11 | Entered in the register |
FAQ
Last updated: 2026-07-16